WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced it has appointed Patrick Bennett as executive director of laboratory operations for a new biomarker services division of its bioanalytical laboratory.
“Patrick brings more than 25 years of experience in laboratories and biomarker services,” said David Johnston, Ph.D., PPD’s executive vice president of global laboratory services. “At PPD, our bioanalytical labs provide state-of-the-art facilities and instrumentation, scientific expertise, experienced regulatory staff and capabilities in a wide variety of technologies and methods. Patrick will lead and drive strategy for comprehensive biomarker development and testing from discovery through approval of predictive medicine biomarkers for both large and small molecule therapeutics.”
With facilities in Richmond, Va., and Middleton, Wis., PPD’s bioanalytical labs provide accurate, high-quality results across all phases of drug development and commercialization delivered in a good laboratory practice (GLP)-compliant setting. Services include customized biomarker measurement; comprehensive, state-of-the-art assay development; method development, validation, transfer and sample analysis in multiple biological species and matrices; validated methods to quantitatively measure all types of compounds; chromatography; immunochemistry; and metabolite identification.
Most recently, Bennett was global strategic marketing director for pharma/biopharma life sciences mass spectrometry at Thermo Fisher Scientific, where he led efforts to develop, manage and implement marketing strategies. Before Thermo Fisher, he served as vice president of business development and marketing and executive laboratory director at Tandem Labs, where he managed scientific and regulatory leadership activities.
He holds a bachelor’s in toxicology and master’s in pharmacology from St. John’s University and received his Master of Business Administration in marketing from Syracuse University.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s bioanalytical laboratory services, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.